| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TCAP |
| Uniprot No | O15273 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-167aa |
| 氨基酸序列 | MATSELSCEVSEENCERREAFWAEWKDLTLSTRPEEGCSLHEEDTQRHETYHQQGQCQVLVQRSPWLMMRMGILGRGLQEYQLPYQRVLPLPIFTPAKMGATKEEREDTPIQLQELLALETALGGQCVDRQEVAEITKQLPPVVPVSKPGALRRSLSRSMSQEAQRG |
| 预测分子量 | 46.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TCAP重组蛋白的3篇虚构参考文献示例，格式包含文献名称、作者及摘要概括：
---
1. **文献名称**: *Expression and Functional Characterization of Recombinant TCAP Protein in T-Cell Activation*
**作者**: Smith, J.R.; Lee, H.; Zhang, Q.
**摘要**: 本研究通过原核表达系统成功表达并纯化了TCAP重组蛋白，验证其在体外可显著增强CD4+ T细胞的增殖与细胞因子分泌，表明TCAP在调节适应性免疫中的潜在应用价值。
2. **文献名称**: *TCAP Recombinant Protein Attenuates Autoimmune Response in Murine Models*
**作者**: Garcia, M.; Patel, S.; Kim, Y.
**摘要**: 通过在小鼠类风湿性关节炎模型中注射TCAP重组蛋白，发现其能抑制过度活化的T细胞并减少炎性因子IL-17水平，提示TCAP或可作为自身免疫疾病的治疗靶点。
3. **文献名称**: *Structural Analysis and Binding Mechanism of TCAP to TCR/CD28 Complex*
**作者**: Wang, L.; Ito, T.; Chen, X.
**摘要**: 利用X射线晶体学解析TCAP重组蛋白的三维结构，并证明其通过结合T细胞受体(TCR)共刺激信号域促进免疫突触形成，为设计基于TCAP的免疫增强剂提供了结构基础。
---
以上示例展示了TCAP重组蛋白在表达优化、疾病治疗及分子机制方面的研究方向，供参考使用。如需真实文献，建议通过PubMed或Web of Science以关键词“TCAP recombinant protein”检索。
TCAP (Tissue Calmodulin-Affinity Protein) recombinant protein is a biologically engineered molecule derived from the TCAP gene, which encodes a small, highly conserved peptide primarily expressed in vertebrates. Initially identified in teleost fish, TCAP is part of the corticotropin-releasing hormone (CRH) family and shares structural homology with stress-related neuropeptides. It plays a regulatory role in cellular stress responses, energy metabolism, and cytoskeletal organization by interacting with calmodulin, a calcium-binding signaling protein. TCAP’s ability to modulate intracellular calcium dynamics and actin polymerization makes it critical in processes like neuronal development, tissue repair, and adaptive responses to environmental stressors.
Recombinant TCAP is produced using prokaryotic or eukaryotic expression systems (e.g., E. coli, yeast, or mammalian cells) to ensure proper folding and post-translational modifications. Its production involves cloning the TCAP gene into expression vectors, followed by purification via affinity chromatography. This approach enables large-scale synthesis of bioactive TCAP for research and therapeutic applications.
Recent studies highlight TCAP’s potential in treating neurological disorders, cardiovascular diseases, and metabolic syndromes. It exhibits neuroprotective effects by reducing apoptosis and enhancing synaptic plasticity, suggesting utility in Alzheimer’s or traumatic brain injury models. Additionally, TCAP influences cardiomyocyte function and vascular remodeling, positioning it as a candidate for heart failure therapies. Its role in glucose homeostasis and adipose regulation also links it to diabetes and obesity research.
Despite promising preclinical data, challenges remain in optimizing delivery methods, stability, and tissue-specific targeting. Ongoing research aims to elucidate TCAP’s signaling mechanisms and expand its clinical translatability, bridging molecular insights with therapeutic innovation.
×
